<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>999</ReferenceId>
        <DateLastUpdated>2020-09-10-07:00</DateLastUpdated>
        <Article>
            <PubmedId>10859378</PubmedId>
            <Abstract>Monoclonal antibody (MAb) IIB4 displays a rare combination of virus neutralization (VN) activity and broad cross-reactivity with influenza A virus strains of the H3 subtype isolated in a period from 1973 to 1988. The epitope of this antibody has been identified as around HA1 residues 198, 199 and 201. Here we report that residues 155, 159, 188, 189 and 193 also influence the binding of this antibody. We have used this antibody to study the relationship between antibody affinity and VN activity. Using one MAb and a single epitope on the haemagglutinin (HA) of different influenza viruses we found a strong positive correlation between effective affinity and VN activity of MAb IIB4. A 10-fold increase in effective affinity corresponded to the 2000-fold increase in VN titre. It follows from the law of mass action that for an effective affinity K=9x10(8) l/mol, 50% VN was achieved at approx. 10% occupation of HA spikes with antibody. In contrast, for an effective affinity K=6x10(7) l/mol, to achieve 50% VN, occupation of up to 98% of HA spikes was required. An effective affinity about K=6x10(7) l/mol thus represents the limiting value for VN because a further decrease in the affinity cannot be compensated by a higher concentration of antibody.</Abstract>
            <ArticleYear>2000</ArticleYear>
            <ArticlePages>1727-35</ArticlePages>
            <ArticleTitle>The strong positive correlation between effective affinity and infectivity neutralization of highly cross-reactive monoclonal antibody IIB4, which recognizes antigenic site B on influenza A virus haemagglutinin.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Kostolanský</LastName>
                    <ForeName>F</ForeName>
                </Author>
                <Author>
                    <LastName>Varecková</LastName>
                    <ForeName>E</ForeName>
                </Author>
                <Author>
                    <LastName>Betáková</LastName>
                    <ForeName>T</ForeName>
                </Author>
                <Author>
                    <LastName>Mucha</LastName>
                    <ForeName>V</ForeName>
                </Author>
                <Author>
                    <LastName>Russ</LastName>
                    <ForeName>G</ForeName>
                </Author>
                <Author>
                    <LastName>Wharton</LastName>
                    <ForeName>S A</ForeName>
                </Author>
            </Authors>
            <Affiliations>Institute of Virology, Slovak Academy of Sciences, Dúbravská cesta 9, 842 46 Bratislava, Slovak Republic.</Affiliations>
            <ArticleChemicalList>Antibodies, Monoclonal;Antibodies, Viral;Epitopes;Hemagglutinin Glycoproteins, Influenza Virus</ArticleChemicalList>
            <ArticleMeshHeadingsList>Amino Acid Sequence; Animals; Antibodies, Monoclonal(immunology); Antibodies, Viral(immunology); Antibody Affinity; Chickens; Cross Reactions; Epitopes; Hemagglutinin Glycoproteins, Influenza Virus(immunology); Influenza A virus(immunology); Molecular Sequence Data</ArticleMeshHeadingsList>
            <Journal>
                <Volume>81</Volume>
                <Issue>Pt 7</Issue>
                <Title>The Journal of general virology</Title>
                <Issn>1465-2099</Issn>
                <MedlineTa>J Gen Virol</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>HA1 Antigenic Site B epitope</EpitopeName>
                <EpitopeStructure>
                    <DiscontinuousRegionOnAccessionSequenceMolecule>
                        <ChemicalType>Discontinuous protein residues</ChemicalType>
                        <DiscontinuousResidues>A198, S199, R201</DiscontinuousResidues>
                        <SourceMolecule>
                            <GenBankId>P03441.3</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>385630</SourceOrganismId>
                    </DiscontinuousRegionOnAccessionSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Table 1</LocationOfData>
                <EpitopeId>225199</EpitopeId>
                <ReferenceRegion>A198, S199, R201</ReferenceRegion>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Partial Epitope</EpitopeStructureDefines>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 2</LocationOfData>
                        <BCellId>13573</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>385630</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Influenza A virus (A/Bangkok/1/79 (H3N2))</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>316</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>A comparison of hemagglutination and virus neutralization capacity of mAb IIB4 against several wild-type strains of Influenza A virus was used to generate a correlation between HI and VN.  VN reactivity of Mab IIB4 roughly correlates with its binding reactivity in ELISA. VN&lt;sub&gt;50&lt;/sub&gt; values &lt;100 ng were:  A/Victoria/3/75 =80, A/Bangkok/1/79 = 5, A/Belgium/2/81 = 2.5, A/Philippines/2/82 = 5, A/Praha/2/83 HI+ =5, and A/Mississippi/1/85.   A/Dunedin/4/73 and A/England/427/88 both had an intermediate VN&lt;sub&gt;50&lt;/sub&gt; value of 5000 ng.  VN&lt;sub&gt;50&lt;/sub&gt; values &gt;10000  corresponded to: A/Hong Kong/1/68, A/England/42/72, A/Praha/2/83 HI-, A/Caen/1/84, and A/England/427/88.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Purified Immunoglobulin</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>mAb IIB4</AssayedAntibodyName>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>Influenza A -various strains</AntigenReferenceName>
                            <AntigenConformation>Native</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                <Object>
                                    <Organism>
                                        <SubType>Organism</SubType>
                                        <SourceOrganismId>41857</SourceOrganismId>
                                    </Organism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Representative selection</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 2</LocationOfData>
                        <BCellId>13572</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>385630</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Influenza A virus (A/Bangkok/1/79 (H3N2))</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>231</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>HI titres ranged from &lt;20 (dilution-1) to 4096.  A comparison of hemagglutination and virus neutralization capacity of mAb IIB4 against several wild-type strains of Influenza A virus was used to generate a correlation between HI and VN.  VN reactivity of Mab IIB4 roughly correlates with its binding reactivity in ELISA.  HI sensitive Influenza virus strains tested were:  A/Dunedin/4/73, A/Victoria/3/75, A/Bangkok/1/79/, A/Belgium/2/81, A/Philippines/2/82, A/Praha/2/83 HI+, and A/Mississippi/1/85.   HI resistant strains tested were: A/Hong Kong/1/68, A/England/42/72, A/Praha/2/83 HI-, A/Caen/1/84, and A/England/427/88.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>mAb IIB4</AssayedAntibodyName>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>Influenza A virus-various strains</AntigenReferenceName>
                            <AntigenConformation>Native</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                <Object>
                                    <Organism>
                                        <SubType>Organism</SubType>
                                        <SourceOrganismId>41857</SourceOrganismId>
                                    </Organism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Representative selection</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 2</LocationOfData>
                        <BCellId>17770</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>385630</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Influenza A virus (A/Bangkok/1/79 (H3N2))</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>199</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Effective binding affinities (l/mol) of mAb IIB4 against several wild-type strains of Influenza A virus were determined to be in the range of 6.1x10&lt;sup&gt;7&lt;/sup&gt; to 8.7x10&lt;sup&gt;8&lt;/sup&gt;.  A plot of Keff'' v. ng to produce VN&lt;sub&gt;50&lt;/sub&gt; was used to produce %occupancy values which ranged from 13.5% - 98%. Strains tested were: A/Dunedin/4/73, A/Victoria/3/75, A/Bangkok/1/79/, A/Belgium/2/81, A/Philippines/2/82, A/Praha/2/83 HI+, and A/Mississippi/1/85,  and A/England/427/88.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Purified Immunoglobulin</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>mAb IIB4</AssayedAntibodyName>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>Influenza A virus-various strains</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                <Object>
                                    <Organism>
                                        <SubType>Organism</SubType>
                                        <SourceOrganismId>41857</SourceOrganismId>
                                    </Organism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Representative selection</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

